TVM Capital

TVM Capital

the home of AI info

Arteris IP FlexNoC Interconnect and AI Package Licensed by Vastai Technologies for Artificial ...

MedCity News

bluebird bio's stock tanks after report of serious toxicity in sickle cell patient

$60,000,000 Venture capital
FinSMEs , PE HUB

Rapid Micro Biosystems Secures $60M in Equity Financing

Funding
$30,000,000 Post-IPO debt
businesswire , PE HUB

Concert Pharmaceuticals Announces $30 Million Venture Debt Financing from Hercules Capital

Xconomy

Proteon Therapeutics Plans Path Forward for Blood Vessel Drug

Health
$250,000,000 Post-IPO equity
Twitter

Boston Business on Twitter

The Motley Fool

Better Buy: Agenus Inc. vs. bluebird bio

The Motley Fool

Why Global Blood Therapeutics Inc. Skyrocketed and bluebird bio Inc. Sank Today

The Motley Fool

Better Buy: bluebird bio vs. Inovio Pharmaceuticals

The Motley Fool

Better Buy: Juno Therapeutics vs. bluebird bio

The Motley Fool

bluebird bio Inc: Catnapping in Cambridge

The Motley Fool

Forget Bluebird Bio, Inc.: These 3 Stocks Are Better Buys

The Motley Fool

bluebird bio, Inc. Takes Flight Towards First Approval

The Motley Fool

Here's Why bluebird bio.'s Stock Tumbled in March

The Motley Fool

Why bluebird bio's Stock Jumped 12.9% on Wednesday

The Motley Fool

Better Buy: bluebird bio, Inc. vs. Alnylam Pharmaceuticals

The Motley Fool

Why Bluebird Bio Inc. Plunged Today

The Motley Fool

Why bluebird bio Inc Presented a Lower Price Today

The Motley Fool

Why bluebird bio Inc, Juno Therapeutics Inc, and Alnylam Pharmaceuticals, Inc. Jumped Today

Stock markets
The Motley Fool

Why bluebird bio Inc.'s Stock Dropped 34% in January

Stock markets